Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

In vivo cardiac pacemaker function of differentiated human mesenchymal stem cells from adipose tissue transplanted into porcine hearts.

Darche FF., Rivinius R., Rahm AK., Köllensperger E., Leimer U., Germann G.

Animal Study with a reported sample of 6 on Cardiovascular Disease, published in World J Stem Cells (2020) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
World J Stem Cells (2020)
Country
United States
Reported sample size
6
Source database
PubMed
PMID
33178397
DOI
10.4252/wjsc.v12.i10.1133

Abstract (original English)

Mesenchymal stem cells (MSC) modified by gene transfer to express cardiac pacemaker channels such as HCN2 or HCN4 were shown to elicit pacemaker function after intracardiac transplantation in experimental animal models. Human MSC derived from adipose tissue (haMSC) differentiate into cells with pacemaker properties in vitro , but little is known about their behavior after intracardiac transplantation. To investigate whether haMSC elicit biological pacemaker function in vivo after transplantation into pig hearts. haMSC under native conditions (nhaMSC) or after pre-conditioning by medium differentiation (dhaMSC) ( n = 6 pigs each, 5 × 10 6 cells/animal) were injected into the porcine left ventricular free wall. Animals receiving PBS injection served as controls ( n = 6). Four weeks later, total atrioventricular (AV)-block was induced by radiofrequency catheter ablation, and electronic pacemaker devices were implanted for backup stimulation and heart rate monitoring. Ventricular rate and rhythm of pigs were evaluated during a follow-up of 15 d post ablation by 12-lead-ECG with heart rate assessment, 24-h continuous rate monitoring recorded by electronic pacemaker, assessment of escape recovery time, and pharmacological challenge to address catecholaminergic rate response. Finally, hearts were analyzed by histological and immunohistochemical investigations. In vivo transplantation

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research